Date: 2014-09-03
Type of information: Publication of results in a medical journal
phase:
Announcement: publication of results in the journal Cancer
Company: Myriad Genetics (USA - UT)
Product: myRisk™ Hereditary Cancer test
Action
mechanism: The myRisk test uses next-generation sequencing technology to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.
Disease: breast cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 3, 2014, Myriad Genetics announced that the Myriad myRisk™ Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer (http://onlinelibrary.wiley.com/doi/10.1002/cncr.29010/abstract). In this study, researchers at Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center used the myRisk test to determine the frequency of hereditary cancer mutations in 2,158 individuals with a history of breast cancer, including 1,781 referred for commercial BRCA1/2 testing, and 377 patients with a personal and family history who previously tested negative for BRCA mutations.
Deleterious mutations were found in a total of 16 genes. Among the 1,781 patients referred for commercial BRCA testing, 9.3 percent carried a mutation inBRCA1 or BRCA2. Importantly, an additional 4 percent of patients carried a mutation in another breast and ovarian cancer susceptibility gene. Among the 377 patients with personal and family histories who previously tested negative for BRCA mutations, the frequency of mutations in the other breast and ovarian cancer susceptibility genes was nearly 3 percent. Additionally, among the 1,781 patients referred for commercial BRCA testing, 0.4 percent of individuals had mutations in colon cancer (Lynch-syndrome) genes. The myRisk Hereditary Cancer test increased the detection of cancer-causing mutations in genes other than BRCA1 or BRCA2 by 46 percent and found 43 percent more women with a deleterious mutation. Most of these new mutations were in other cancer susceptibility genes associated with breast/ovarian cancer such as CHEK2, PALB2 and ATM.
